Cargando…

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension

Hypertension is found frequently in patients with COVID-19 and is often treated with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). SARS-CoV-2, the pathogen of COVID-19, binds to the receptors of ACE2 to enter the alveolar cells, raising questions on whether these drugs are salutar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzeytemiz, Mustafa, Tenekecioglu, Erhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753108/ https://www.ncbi.nlm.nih.gov/pubmed/34987107 http://dx.doi.org/10.1136/jim-2021-002036

Ejemplares similares

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry
por: Angeli, Fabio, et al.
Publicado: (2022)

The Association between Chronic Use of Renin–Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension
por: Cetinkal, Gokhan, et al.
Publicado: (2020)

Association of renin–angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study
por: Soler, María José, et al.
Publicado: (2021)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
por: Theodorakopoulou, Marieta P, et al.
Publicado: (2021)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Predictors of coronary collaterals in patients with non ST-elevated acute coronary syndrome: the paradox of the leukocytes
por: Tenekecioglu, Erhan, et al.
Publicado: (2014)

Disturbed Left Atrial Function is Associated with Paroxysmal Atrial Fibrillation in Hypertension
por: Tenekecioglu, Erhan, et al.
Publicado: (2014)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
por: Lee, Jinwoo, et al.
Publicado: (2021)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
por: Laurentius, Andrea, et al.
Publicado: (2021)

Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
por: Filev, Rumen, et al.
Publicado: (2022)

Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
por: Morales, Daniel R, et al.
Publicado: (2020)

Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients
por: Kawabata, Yutaka, et al.
Publicado: (2020)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

Impact of Renin‐Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery
por: Antoniak, Derrick T., et al.
Publicado: (2021)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation
por: Rodriguez-Padial, Luis, et al.
Publicado: (2017)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection
por: Salah, Husam M., et al.
Publicado: (2020)

Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19
por: Silva, Mauro G., et al.
Publicado: (2022)

Position Paper of the Department of Hypertension of the Brazilian Society of Nephrology: Use of renin-angiotensin system blockers during the course of Covid-19 infection
por: Rodrigues, Cibele Isaac Saad
Publicado: (2020)

Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
por: Mahajan, Kunal, et al.
Publicado: (2020)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan
por: Yoshihara, Fumiki, et al.
Publicado: (2022)

Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence
por: Turgeon, Ricky D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbeobkaqlm8cpj6cmktq812je1